Anavex Life Sciences Corp (AVXL)

[Joseph_K]

Does Missling have privileged scientific knowledge of blarcamesine?

Investor, you said,

Missling have thoughts, plans and perhaps even some doubts and concerns about A2-73 that we cannot be aware of, but fundamental knowledge about the compound, it’s proposed MoA and effects he likely gets from the same places we read it.

I'm strongly inclined to disagree, but happy to hear a rebuttal. I find falconer66a's post believable and at this point convincing.

Do you believe Anavex has not been "privately experimenting with their molecules in murines (lab rodents) and other lab test animals," that they do not "know quite accurately how their molecules force neurons to function normally ..."? It makes sense to me that Anavex does, or funds others who are bound to confidentiality, to do this sort of research, and that Anavex is not only a company of administrators who buy rights to promising molecules, file patents, and arrange for clinical trials, but also a company that privately funds cutting-edge scientific research on the biological effects of its therapeutic candidates on the sigma-1 receptor and the processes downstream from it.* Furthermore, if falconer is correct, then Anavex would perform not only such fundamental research, but research on its molecules' potential effect on the diseases it considers as possible targets, and it would hold such research in confidence at this point.

If what falconer said in that post is true, then Missling surely would have "fundamental knowledge about the compound, it’s proposed MoA, and effects" well beyond what we get to read about.


*It more than just "makes sense to me," because we know they publish some of these studies. Additional research has almost certainly been conducted but not published. I expect some is not yet published for reasons of competitive advantage. There seems to be an uptick in academic research on sigma-1 agonists, but the field is far from flooded and there must be significant aspects not studied by others, and certainly not yet published, that Anavex had delved into.